WO2025215561 - PLASMID FOR EXPRESSION OF KSP37
National phase entry is expected:
Publication Number
WO/2025/215561
Publication Date
16.10.2025
International Application No.
PCT/IB2025/053748
International Filing Date
09.04.2025
Title **
[English]
PLASMID FOR EXPRESSION OF KSP37
[French]
PLASMIDE POUR L'EXPRESSION DE KSP37
Applicants **
VIRO-GEN (PTY) LTD
Inventors
ALEXANDRE, Kabamba Bankoledi
SMIT, Michelle Olga Patricia Giesteira Da Silva
Priority Data
2024/02708
09.04.2024
ZA
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
APO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2352 | |
| EPO | Filing, Examination, Granting | 13769 | |
| Japan | Filing, Examination, Granting | 2461 | |
| South Korea | Filing, Examination, Granting | 2652 | |
| USA | Filing, Examination, Granting | 8540 |
Total:
29,774
Contact Us
Abstract[English]
This invention relates to a plasmid for expression of Ksp37 and more particularly, but not exclusively, to a plasmid for expression of Ksp37 in eukaryotic cells, including human cells. The plasmid includes a pNL4-3.luc plasmid backbone from which all HIV-1-associated DNA and an ampicillin resistance gene have been removed and a Ksp37 gene inserted between a PaeR7I-XhoI and a EagI-NotI restriction enzyme recognition site.[French]
La présente invention concerne un plasmide pour l'expression de Ksp37 et, plus particulièrement mais pas exclusivement, un plasmide pour l'expression de Ksp37 dans des cellules eucaryotes, y compris des cellules humaines. Le plasmide comprend un squelette plasmidique pNL4-3.luc à partir duquel tout ADN associé au VIH-1 et un gène de résistance à l'ampicilline ont été éliminés et un gène Ksp37 inséré entre un site de reconnaissance d'enzyme de restriction PaeR7I-XhoI et un site de reconnaissance d'enzyme de restriction EagI-NotI.